TY - JOUR
T1 - Recommendations for the use of botulinum toxin type A in the management of cerebral palsy
AU - Graham, H. Kerr
AU - Aoki, K. Roger
AU - Autti-Rämö, Ilona
AU - Boyd, Roslyn N.
AU - Delgado, Mauricio R.
AU - Gaebler-Spira, Deborah J.
AU - Gormley, Mark E.
AU - Guyer, Barry M.
AU - Heinen, Florian
AU - Holton, Andrew F.
AU - Matthews, Dennis
AU - Molenaers, Guy
AU - Motta, Francesco
AU - García Ruiz, Pedro J.
AU - Wissel, Jörg
PY - 2000/2
Y1 - 2000/2
N2 - Botulinum toxin type A (BTX-A) is increasingly being used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication has been unapproved with no generally accepted treatment protocols, resulting in considerable uncertainty and variation in its use as a therapeutic agent. In view of the increasing awareness of, and interest in, this approach to the treatment of spasticity, and also the recent licensing in a number of countries of a BTX-A preparation for treating equinus deformity in children, it would seem timely to establish a framework of guidelines for the safe and efficacious use of BTX-A for treating spasticity in children. This paper represents an attempt, by a group of 15 experienced clinicians and scientists from a variety of disciplines, to arrive at a consensus and produce detailed recommendations as to appropriate patient selection and assessment, dosage, injection technique and outcome measurement. The importance of adjunctive physiotherapy, orthoses and casting is also stressed. Copyright (C) 2000 Elsevier Science B.V.
AB - Botulinum toxin type A (BTX-A) is increasingly being used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication has been unapproved with no generally accepted treatment protocols, resulting in considerable uncertainty and variation in its use as a therapeutic agent. In view of the increasing awareness of, and interest in, this approach to the treatment of spasticity, and also the recent licensing in a number of countries of a BTX-A preparation for treating equinus deformity in children, it would seem timely to establish a framework of guidelines for the safe and efficacious use of BTX-A for treating spasticity in children. This paper represents an attempt, by a group of 15 experienced clinicians and scientists from a variety of disciplines, to arrive at a consensus and produce detailed recommendations as to appropriate patient selection and assessment, dosage, injection technique and outcome measurement. The importance of adjunctive physiotherapy, orthoses and casting is also stressed. Copyright (C) 2000 Elsevier Science B.V.
KW - BOTOX®
KW - Botulinum toxin type A
KW - Cerebral palsy
KW - Consensus document
KW - Guidelines
UR - http://www.scopus.com/inward/record.url?scp=17344389543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17344389543&partnerID=8YFLogxK
U2 - 10.1016/S0966-6362(99)00054-5
DO - 10.1016/S0966-6362(99)00054-5
M3 - Review article
C2 - 10664488
AN - SCOPUS:17344389543
SN - 0966-6362
VL - 11
SP - 67
EP - 79
JO - Gait and Posture
JF - Gait and Posture
IS - 1
ER -